Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation granted stock options to a new employee for 742,500 shares of common stock at an exercise price of $1.80 per share, effective February 17, 2026. These inducement grants, approved by Geron’s Compensation Committee, vest over four years and were made in accordance with Nasdaq Listing Rule 5635(c)(4). Geron is a biopharmaceutical company focused on blood cancer treatments.
Top 3 Health Care Stocks That May Collapse This Quarter
This article identifies three healthcare stocks—AstraZeneca (NYSE: AZN), Masimo Corp (NASDAQ: MASI), and Geron Corp (NASDAQ: GERN)—that are currently considered overbought based on their Relative Strength Index (RSI) values. The article details recent positive news and stock performance for each company, such as strong earnings for AstraZeneca, an acquisition for Masimo, and positive financial guidance for Geron, despite their overbought status, signaling potential volatility for investors.
Geron Corporation Reveals 2025 Full Year Financials Amidst Changing Analyst Opinions
Geron Corporation's stock has risen by 10.91% following promising clinical trial results, despite a revised price target from TD Cowen. The company, focused on blood cancer treatments, is preparing to release its Q4 and full year 2025 financial results, which will be crucial for its future trajectory. Investor confidence is growing due to ongoing clinical trials and its evolution into a commercial-stage entity, with analysts observing a speculative yet optimistic outlook.
Geron Corporation: Upcoming Financial Results Spark Market Interest
Geron Corporation's stock (NASDAQ: GERN) has seen a 7.79% increase following positive clinical trial results, though an analyst adjusted the price target while maintaining a Buy rating. The market is keenly awaiting Geron's upcoming financial results to assess its commercial progress, ongoing clinical trials, and overall financial health, especially given its significant investment in research and development. Investors are looking for key insights to determine future moves amidst market speculation.
Candriam S.C.A. Acquires 1,358,068 Shares of Geron Corporation $GERN
Candriam S.C.A. significantly increased its stake in Geron Corporation (NASDAQ:GERN) by 71.6% in the third quarter of 2025, purchasing an additional 1,358,068 shares and bringing its total holdings to 3,253,960 shares. This move highlights growing institutional interest in the biopharmaceutical company, with other funds also adding positions, contributing to a high institutional ownership of 73.71%. Geron, trading around $1.61 with a market cap of $1.03 billion, holds a "Hold" consensus rating and a price target of $2.75, amid mixed analyst opinions.
Geron strategic restructuring plan focuses on Rytelo growth
Geron has announced a strategic restructuring plan aimed at extending its cash runway into the second quarter of 2026. This plan focuses on prioritizing the commercial launch and growth of Rytelo (imetelstat) to maximize its value. The company expects the restructuring to result in an approximately 25% reduction in its workforce by the second half of 2024.
Geron strategic restructuring plan focuses on Rytelo growth
The article states that Geron has implemented a strategic restructuring plan to concentrate its efforts on the growth of its drug, Rytelo. However, no further details or content about this plan or the company were provided in the given text.
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Geron Corporation announced it will release its fourth quarter and full year 2025 financial results and business highlights on February 25, 2026. The results will be available via press release on the company's website, followed by a conference call and webcast at 8:00 a.m. Eastern Time. Geron is a biopharmaceutical company focused on blood cancer, with its telomerase inhibitor RYTELO® (imetelstat) approved for certain adult patients with LR-MDS.
Geron Plans to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Geron Corporation announced it will release its fourth quarter and full year 2025 financial results and business highlights on Wednesday, February 25, 2026, before market open. The company will also host a conference call and webcast at 8:00 a.m. Eastern Time. Geron is a commercial-stage biopharmaceutical company focused on blood cancer, with its telomerase inhibitor RYTELO® approved for certain adult patients with LR-MDS.
Geron Corporation to Release Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Geron Corporation announced it will release its fourth quarter and full year 2025 financial results on February 25, 2026, before market open. A conference call and webcast will follow at 8:00 a.m. Eastern Time. The company, focused on blood cancer treatment, already has its telomerase inhibitor RYTELO® approved in the U.S. and EU and is conducting further pivotal trials.
Geron (NASDAQ:GERN) Shares Cross Above 200 Day Moving Average - Here's What Happened
Geron Corporation (NASDAQ:GERN) shares have recently crossed above their 200-day moving average, trading as high as $1.6275 with a significant volume of 15.38 million shares. The stock has a consensus "Hold" rating from analysts with an average price target of $2.75, following mixed reports, including some reiterating "buy" and "neutral" ratings, and one lowering a price target. Institutional investors have also shown increased activity, with several firms adjusting their positions in the biopharmaceutical company.
Geron Corporation Projects RYTELO Growth Amidst Revised Price Targets
Geron Corporation's stock has risen by 5.48% due to FDA designations and promising results for its RYTELO product. The company projects RYTELO revenue between $220M-$240M for FY26, with operating expenses aligning closely, indicating a stable financial plan. TD Cowen revised Geron’s price target to $3, down from $4, while maintaining a ‘Buy’ rating, reflecting tempered expectations despite long-term confidence.
Geron Corp Projects Major Revenue Boost for 2026
Geron Corporation's stock (NASDAQ: GERN) is up 4.79% following promising developments, including FDA designations. The company projects significant RYTELO product revenues of $220M-$240M for fiscal year 2026 and is expanding its commercial ventures internationally. Despite an analyst lowering the price target to $3 from $4, maintaining a 'Buy' rating, the company faces profitability challenges but retains a positive long-term outlook.
Geron Corporation's (NASDAQ:GERN) Prospects Need A Boost To Lift Shares
Geron Corporation (NASDAQ:GERN) currently has a low price-to-sales (P/S) ratio of 5.4x compared to the biotech industry average, suggesting a bearish outlook from the market. While the company has shown strong historical revenue growth, analysts project a significantly lower annual revenue growth of 39% over the next three years, compared to the industry's 139%. This anticipated underperformance in growth is likely contributing to its subdued P/S ratio, indicating that investors are not currently willing to pay a premium for the stock.
TD Cowen Revises Geron’s Price Target Amid RYTELO Expansion Plans
Geron Corporation's stock has risen by 9.85% following positive FDA designations and promising results for its drug RYTELO. TD Cowen analyst Tara Bancroft adjusted Geron’s price target from $4 to $3 but maintained a Buy rating, as Geron anticipates RYTELO's 2026 revenue to be between $220M and $240M and plans global expansion and further clinical trials. The company is actively focusing on balancing revenue growth with managing operating expenses.
Geron Corporation Anticipates Robust RYTELO Revenue for 2026
Geron Corporation's stock (NASDAQ: GERN) recently saw a 9.38% increase due to promising clinical trial results for its key product, RYTELO, and positive revenue forecasts for 2026. Despite a current net income loss of $18.43 million, the company's strategic investments in U.S. market expansion and the Phase 3 IMpactMF trial indicate a growth-driven strategy. Analysts maintain a "Buy" rating, signaling confidence in Geron's long-term potential as it navigates financial challenges and pursues product expansion.
Investors in Geron Corporation Should Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights - GERN
Levi & Korsinsky LLP has announced that investors in Geron Corporation who suffered losses between February 28, 2024, and February 25, 2025, should contact the firm by May 12, 2025. This call to action follows a class action securities lawsuit alleging that Geron made misleading statements regarding the launch and growth potential of its drug Rytelo. The lawsuit claims that the company minimized risks associated with the drug’s weekly monitoring requirements, leading to a significant stock price drop after financial results revealed flattened growth.
Geron Corporation (NASDAQ:GERN) Given Average Recommendation of "Hold" by Brokerages
Ten analysts covering Geron Corporation (NASDAQ:GERN) have issued a consensus "Hold" rating, with an average 12-month price target of $2.75. The biopharmaceutical company recently reported quarterly earnings of -$0.03 per share, meeting expectations, but its revenue of $47.23 million fell short of analysts' estimates. Institutional investors own a significant portion of the stock, and several have adjusted their positions recently.
TD Cowen Maintains Buy Rating for Geron (GERN) While Trimming PT to $3 Ahead of Q4 Results
TD Cowen analyst Tara Bancroft reduced the firm's price target on Geron (GERN) to $3 from $4 but maintained a Buy rating, ahead of the company's Q4 2025 results. Despite a 15% sequential increase in ordering accounts and initial RYTELO shipments to Germany, Q3 2025 RYTELO demand saw a 3% decline. Geron has restructured and projects $220-$240 million in RYTELO revenue for 2026, aiming for profitability.
TD Cowen Maintains Buy Rating for Geron (GERN) While Trimming PT to $3 Ahead of Q4 Results
TD Cowen analyst Tara Bancroft maintained a Buy rating for Geron (GERN) but reduced the price target from $4 to $3, following an update to the firm's financial model in anticipation of the company's Q4 2025 results. Despite a 15% sequential increase in ordering accounts and an early access program in Germany for RYTELO, demand saw a 3% decline quarter-over-quarter. Geron has since implemented a restructuring, projecting $220 million to $240 million in RYTELO revenue for 2026, aiming for profitability and a stronger commercial presence.
7 Best Fast Growing Penny Stocks to Buy According to Analysts
This article identifies fast-growing penny stocks recommended by analysts, highlighting Geron Corporation (NASDAQ: GERN) as an example. It details Geron's recent performance, including increased ordering accounts, the launch of RYTELO in Germany, and a full enrollment in its Phase 3 trial. Despite a slight dip in RYTELO demand, Geron anticipates significant revenue and profitability in 2026 due to restructuring efforts.
Geron Corporation (GERN) presents new data at the 67th American Society of Hematology 2025 annual meeting
This article announces that Geron Corporation (GERN) will present new data at the 67th American Society of Hematology (ASH) 2025 annual meeting. The presentation highlights the company's ongoing research and potential advancements in the field of hematology.
Geron Corporation (GERN) Streamlines Operations, Secures Financing, Eyes 2026 Growth
Geron Corporation is streamlining operations, securing financing, and positioning for growth in 2026. The company recently amended a loan agreement for up to $250 million and announced a restructuring plan to cut about one-third of its workforce to focus on Rytelo sales and international expansion. Despite recent stagnation in Rytelo sales, analysts anticipate an decline in expenses and potential profitability by the second half of 2026.
Pleasing Signs As A Number Of Insiders Buy Geron Stock
Multiple insiders at Geron Corporation (NASDAQ:GERN) have purchased shares over the last year, sending a positive signal. The most significant purchase involved an insider buying US$160k worth of shares at a price higher than the current market value, suggesting bullish sentiment. While insider ownership generally remains low, the recent buying activity indicates growing insider confidence in the company's future.
Geron forecasts $220-240 million in RYTELO revenue for 2026
Geron Corporation has projected RYTELO net product revenue between $220 million and $240 million for 2026, alongside operating expenses of $230 million to $240 million, driven by focused targeting and international expansion. The company also amended its loan agreement to extend the deadline for requesting additional funding and initiated a strategic restructuring to streamline operations. These financial projections and strategic moves come as RYTELO, a telomerase inhibitor for lower-risk myelodysplastic syndromes, sees continued approval and scientific evidence support.
Geron Shares Potential Strategic Talent Surge After Employee Stock Plan
Geron Corporation's stock has risen by 9.06% following positive FDA designations and the announcement of a stock option grant to a new employee. This strategic move aims to attract top talent and strengthen the company's position in the biotechnology market, signaling a long-term growth strategy despite current financial challenges. Investors are cautiously optimistic, awaiting tangible impacts on performance and profitability.
Geron forecasts $220-240 million in RYTELO revenue for 2026 By Investing.com
Geron Corporation projects RYTELO net product revenue of $220-240 million for 2026, driven by focused commercial strategies and supported by recent strategic restructuring to optimize operations. The company also announced an amendment to its loan facility, extending the deadline for additional funding, and presented new scientific evidence supporting RYTELO at the 2025 American Society of Hematology Annual Meeting. These developments highlight Geron's commitment to expanding RYTELO's market presence and advancing clinical trials.
Geron Corporation Provides 2026 Financial Guidance
Geron Corporation has issued its 2026 financial guidance, projecting RYTELO net product revenue between $220 million and $240 million and total operating expenses in the same range. The company emphasizes a strategy of commercial growth for RYTELO in the U.S. and abroad, alongside advancing its Phase 3 IMpactMF trial, supported by recent strategic restructuring to streamline operations.
Geron Corporation Provides 2026 Financial Guidance
Geron Corporation announced its 2026 financial guidance, projecting RYTELO® net product revenue between $220 million and $240 million and total operating expenses between $230 million and $240 million. The company emphasizes driving commercial growth for RYTELO in the U.S. and abroad, alongside advancing its Phase 3 IMpactMF trial, aiming for sustainable growth and a streamlined operation. This outlook reflects anticipated top-line growth and reduced operating spend due to a strategic restructuring.
Geron (GERN) plans restructuring to cut costs, HC Wainwright stays neutral
Geron (GERN) has announced a restructuring plan aimed at reducing costs and optimizing operations, coinciding with HC Wainwright maintaining a neutral stance on the company's stock. This move by Geron suggests a strategic effort to improve financial efficiency. The analyst's unchanged rating indicates a cautious but not negative outlook on the company's prospects following the announced changes.
Geron (GERN) Plans Restructuring to Cut Costs, H.C. Wainwright Stays Neutral
Geron Corporation (NASDAQ: GERN) is undertaking a strategic restructuring plan to reduce costs, including a one-third workforce reduction, aiming for long-term value creation and improved financial discipline. H.C. Wainwright maintained a Neutral rating, expecting the company to reach profitability in the second half of 2026 due to anticipated lower operating expenses. The restructuring also focuses on commercial growth for RYTELO and progress on the Phase 3 IMpactMF trial.
Geron (GERN) Plans Restructuring to Cut Costs, H.C. Wainwright Stays Neutral
Geron Corporation (GERN) announced a strategic restructuring plan to reduce its workforce by about one-third and streamline operations, aiming for long-term value creation and improved financial discipline. H.C. Wainwright maintained a Neutral rating, noting that the plan is expected to lower 2026 operating expenses and could lead to profitability in the second half of 2026. The company plans to focus on RYTELO commercial growth, international expansion, and progress on its Phase 3 IMpactMF trial.
Geron extends loan agreement deadlines for $250 million credit facility
Geron Corporation announced an amendment to its $250 million senior secured term loan facility, extending the deadlines for requesting Tranche B and Tranche C loans from December 31, 2025, to July 30, 2026. The biotech company maintains a strong liquidity position, and the amendment also pushes the makewhole date for prepayments from November 1, 2026, to May 1, 2027. This news comes alongside a strategic restructuring plan, workforce reduction, and mixed analyst ratings concerning its drug Rytelo.
Geron Amends Term Loan Facility to Extend Draw Deadlines
Geron (GERN) has amended its senior secured term loan facility with Pharmakon Advisors, extending the draw deadlines for Tranche B and Tranche C loans from December 31, 2025, to July 30, 2026. This amendment, made on January 5, 2026, also pushes the makewhole protection date for lenders, providing Geron greater flexibility in its borrowing schedule and supporting its future funding and growth needs. Despite some financial challenges, the company's product RYTELO™ is tied to revenue milestones in the $250 million facility.
Geron extends loan agreement deadlines for $250 million credit facility By Investing.com
Geron Corporation has amended its $250 million senior secured term loan facility, extending the deadlines for requesting Tranche B and Tranche C loans from December 31, 2025, to July 30, 2026. The biotech company retains strong liquidity and the option to prepay loans, subject to premiums and makewhole amounts. This amendment follows a strategic restructuring and recent presentations on its drug Rytelo at ASH 2025, amidst varied analyst ratings.
Geron (NASDAQ:GERN) Trading Up 4.9% - Time to Buy?
Geron Corporation's stock (NASDAQ:GERN) saw a 4.9% increase in mid-day trading but with light volume, amidst mixed analyst ratings and an average "Hold" recommendation. The company, focused on telomerase inhibitors for cancer, reported a negative Q3 EPS and revenue miss, yet investor interest is driven by its lead drug, imetelstat, in late-stage trials. Despite recent FDA panel approval for imetelstat, the company faces financial challenges, and analysts maintain a cautious outlook.
Geron (NASDAQ:GERN) Shares Down 3.9% - What's Next?
Geron (NASDAQ:GERN) saw its shares drop 3.9% during midday trading to $1.345, with trade volume significantly lower than its daily average. Analyst ratings are mixed, with a consensus "Hold" and an average price target of $2.75, following recent adjustments including a price target cut by Needham. The biopharmaceutical company reported an in-line EPS but missed revenue expectations last quarter and holds a market capitalization of approximately $855 million.
Shareholders that lost money on Geron Corporation(GERN) should contact Levi & Korsinsky about pending Class Action - GERN
A class action lawsuit has been filed against Geron Corporation (NASDAQ:GERN) seeking to recover losses for shareholders who suffered due to alleged securities fraud between February 28, 2024, and February 25, 2025. The lawsuit claims Geron misrepresented the launch and growth potential of its drug Rytelo, leading to a significant stock price decline when the company revealed flattened growth. Shareholders are encouraged to contact Levi & Korsinsky to learn about their rights.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced that it granted stock options to a new employee as an inducement material to their acceptance of employment. This grant, in accordance with Nasdaq Listing Rule 5635(c)(4), involves 320,000 shares of common stock with an exercise price of $1.34 per share, vesting over four years. The company is a commercial-stage biopharmaceutical firm focused on blood cancer, with its telomerase inhibitor RYTELO® (imetelstat) approved for certain myelodysplastic syndromes.
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation announced that it has granted stock options to a newly hired employee as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The grant involves 320,000 shares of common stock with an exercise price of $1.34 per share, vesting over four years. This action is part of the company's efforts as a commercial-stage biopharmaceutical firm focused on blood cancer treatments.
Geron Corporation (GERN) Restructuring to Lower Operating Expenses as it Eyes Profitability in 2026
Geron Corporation (NASDAQ: GERN) has announced a strategic restructuring plan, including a one-third workforce reduction, to lower operating expenses and achieve profitability by the second half of 2026. The biopharmaceutical company aims to streamline operations while focusing on the commercialization of its flagship treatment, RYTELO, and advancing its Phase 3 ImpactMF trial. Analysts at H.C. Wainwright maintain a Neutral rating, expecting reduced operating expenses to lead to profitability in 2026.
Shareholders That Lost Money on Geron Corporation (GERN) Should Contact Levi & Korsinsky About Pending Class Action - GERN
Levi & Korsinsky LLP has filed a class action securities lawsuit against Geron Corporation (NASDAQ:GERN) on behalf of shareholders who suffered losses between February 28, 2024, and February 25, 2025. The lawsuit alleges that Geron provided misleading information regarding the launch and growth potential of its drug Rytelo, while downplaying risks. Following an announcement of Rytelo's flattened growth and attributing it to seasonality, competition, and monitoring burdens, Geron's stock price dropped by over 32% in one day.
Geron Corporation Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 12, 2025 to Discuss Your Rights - GERN
Levi & Korsinsky LLP has filed a class action securities lawsuit against Geron Corporation (NASDAQ:GERN), alleging securities fraud impacting shareholders between February 28, 2024, and February 25, 2025. The lawsuit claims Geron misled investors regarding the launch and growth potential of its drug Rytelo (imetelstat), particularly by understating risks associated with monitoring requirements, seasonality, and competition. Geron's stock price declined significantly after the company disclosed Rytelo's flattened growth and attributed it to these factors on February 26, 2025.
14 Best Multibagger Penny Stocks to Buy Right Now
This article highlights Geron Corporation (NASDAQ:GERN) as one of the best multibagger penny stocks. The company recently announced a strategic restructuring plan to reduce operating expenses and workforce by a third, aiming for profitability by the second half of next year. Geron is also focusing on commercializing its flagship treatment RYTELO and advancing a Phase 3 ImpactMF trial.
Shareholders That Lost Money on Geron Corporation (GERN) Should Contact Levi & Korsinsky about Pending Class Action - GERN
Levi & Korsinsky, LLP has filed a class action lawsuit against Geron Corporation (NASDAQ: GERN) on behalf of shareholders who suffered losses between February 28, 2024, and February 25, 2025. The lawsuit alleges securities fraud concerning Geron's statements about the launch and growth potential of its drug Rytelo, particularly downplaying risks associated with its monitoring requirements. Following news of flattened growth and diminished sales on February 26, 2025, Geron's stock price dropped by approximately 32.07%.
Geron Corporation (NASDAQ: GERN) plans workforce cuts, expects $18M charges
Geron Corporation is implementing a strategic restructuring plan, including a workforce reduction of approximately one-third of its 260 employees. The company expects to incur about $18 million in restructuring and related charges, primarily for severance and employee costs, which will impact financial results in Q4 2025 and Q1 2026. This repositioning aims for long-term value creation and improved financial discipline, with the workforce reduction expected to be substantially complete by Q1 2026.
Bay Area biotech company, down $1.7 billion in value, lays off a third of staff
Geron Corporation, a Bay Area biotech company, announced it is laying off a third of its staff, impacting approximately 85 employees. This decision, described as "prudent fiscal management" by CEO Harout Semerjian, aims to reduce operating expenses despite the recent commercial launch and growing sales of its blood cancer drug, Rytelo. The company's valuation has significantly declined from over $2.5 billion to around $860 million since its drug received FDA approval.
Geron (NASDAQ:GERN) Is Using Debt Safely
Geron Corporation (NASDAQ:GERN) effectively manages its debt, leveraging US$119.3m in debt against US$380.5m in cash, resulting in a net cash position of US$261.3m. The company's strong liquid assets, totaling US$99.5m more than its total liabilities, suggest it can comfortably cover its financial obligations. Despite being a loss-making company with negative free cash flow, significant revenue growth and substantial cash reserves indicate Geron can sustain operations and growth for at least two years.
Geron Corporation Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - GERN
Geron Corporation is being sued for federal securities law violations following a class action lawsuit filed against the company. The lawsuit alleges that Geron provided misleading information regarding the launch and growth potential of its drug Rytelo, failing to adequately disclose risks. This led to a significant 32.07% stock price drop after the company announced diminished growth for Rytelo.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bancorp, Geron, enCore, and TFI and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. has filed class action lawsuits against The Bancorp, Inc. (NASDAQ: TBBK), Geron Corporation (NASDAQ: GERN), enCore Energy Corp. (NASDAQ: EU), and TFI International Inc. (NYSE: TFII). The lawsuits allege that these companies made materially false and/or misleading statements regarding their business operations, prospects, and financial reporting. Investors affected by these companies are encouraged to contact Bragar Eagel & Squire, P.C. to potentially serve as lead plaintiff in the class actions.
